FDA Approves SAXAGLIPTIN AND METFORMIN — Mylan Pharmaceuticals Inc.
Mylan Pharmaceuticals Inc. announced on Friday the U.S. approval of its ANDA for saxagliptin and metformin, initiating a new competitive entry into the expanding diabetes market segment. This regulatory progress positions the manufacturer to capture market share from established Theraset (Omar Lilium) products facing postmarketing concerns.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed